TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00636012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: acupuncture at St36 and Pe6

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: superficial needling at sham points
Study: NCT02621073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VeraFlo with Prontosan
Description: VeraFlo device with Prontosan instillation (n=10).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V.A.C Ulta System
Description: V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
Study: NCT04024423

Intervention type: OTHER
Intervention: Epidemiologic investigation
Description: Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.

Intervention type: OTHER
Intervention: Epidemiologic investigation
Description: Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.

Intervention type: OTHER
Intervention: Epidemiologic investigation
Description: Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.

Intervention type: OTHER
Intervention: Epidemiologic investigation
Description: Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
Study: NCT02249377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelets-Rich-Plasma
Description: Platelet-Rich Plasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid
Study: NCT00372944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: oral tablet
Study: NCT00763373

Intervention type: OTHER
Intervention: Implementation of antibiotic switch guidelines
Description: Implementation of antibiotic switch guidelines
Study: NCT02879435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: pre-operative wound infiltration with 10 ml of numbing medicine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pre-operative wound infiltration with 10 ml of sterile water
Study: NCT02253173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04532099

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational soft contact lenses for daily wear worn in Part A of the study

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational soft contact lenses for daily wear worn in Part A of the study
Study: NCT03390166

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GPO Tri Fluvac vaccine
Description: The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed influenza vaccine
Description: The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
Study: NCT00519207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
Study: NCT04024423

Intervention type: OTHER
Intervention: Epidemiologic investigation
Description: Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
Study: NCT00519207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% Sucrose Solution
Description: 2ml of 24% sucrose will be administered 2 minutes prior to venipuncture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% Sucrose Solution
Description: 2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
Study: NCT02216084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant ADAMTS13
Description: rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3).
Study: NCT03020433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Contralesional M1
Description: 1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Contralesional PMC
Description: 5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS Ipsilesional PMC
Description: 5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS sham at Ipsilesional M1
Description: 1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
Study: NCT01052272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
Study: NCT01560299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: Methimazole was stopped 24-48 before radio-iodine therapy
Study: NCT02715570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - single doses
Description: Safety and tolerability of single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - single doses
Description: Safety and tolerability of single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945 - repeat doses
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - repeat doses
Description: Safety and tolerability of repeat doses
Study: NCT03120325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulation
Description: Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulation
Description: Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulation
Description: Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
Study: NCT01560299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: methimazole discontinued 49-72 hours before radioiodine treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: methimazole discontinued 73-168 hours before radio-iodine treatment
Study: NCT01052272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
Study: NCT02520921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novel strategy Aspirin
Description: Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional strategy Aspirin
Description: Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
Study: NCT03648216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA behavioural counseling
Description: Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
Study: NCT04326816

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)
Study: NCT04052776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa-Carbidopa
Description: 400mg/100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone + Levodopa-Carbidopa
Description: 40mg + 400mg/100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Non-active metabolite
Study: NCT02698722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End-stage renal disease treatment options
Description: This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
Study: NCT02349490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )
Description: Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )
Description: Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
Study: NCT02265796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
Study: NCT02035722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed materials
Description: AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: AMD-related information is presented as in the form of a video
Study: NCT01107938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg ilaprazole
Description: Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg esomeprazole
Description: One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
Study: NCT04532099

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Commercially available soft contact lenses for daily wear worn in Part A of the study

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Commercially available soft contact lenses for daily wear worn in Part A of the study
Study: NCT01052272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: The starting dose of Allopurinol is 300 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: The starting dose of Allopurinol is 300 mg daily.
Study: NCT02757378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroplasticity Explanation (Experimental)
Description: Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
Study: NCT04532099

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Commercially available soft contact lenses for daily wear worn in Part B of the study

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based cleaning and disinfecting solution
Description: For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogen peroxide-based cleaning and disinfecting solution
Description: For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based cleaning and disinfecting solution
Description: For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
Study: NCT02696642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
Study: NCT04474951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stinging Nettle
Description: Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of anemia.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stinging Nettle
Description: Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of fatigue.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peppermint
Description: Eligible patients will take 40 drops TID of Fluid Extract of Peppermint for control of nausea.
Study: NCT03724812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico Valve and FlexNav™ Delivery System
Description: Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
Study: NCT00652236

Intervention type: OTHER
Intervention: Physiotherapy
Description: The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
Study: NCT00402493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen, latanoprost, brimonidine
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Study: NCT03842384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iENDURE
Description: The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
Study: NCT03103997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy
Description: EUS-guided liver biopsy using needles with various preparations
Study: NCT02736149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ubenimex
Study: NCT02757378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biomechanical Explanation (Control)
Description: Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
Study: NCT02697656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS
Description: Individualized job support provided by an employment specialist
Study: NCT00402493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen, latanoprost, brimonidine
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen, latanoprost, brimonidine
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Study: NCT02962973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARMAT TAH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Study: NCT00872586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide
Description: olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil
Description: olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
Study: NCT02475564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40mg of starch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 40mg of resveratrol (powder)
Study: NCT02384629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI with AXXESS stent
Description: The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
Study: NCT03103997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided liver biopsy
Description: EUS-guided liver biopsy using needles with various preparations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy
Description: EUS-guided liver biopsy using needles with various preparations
Study: NCT01109225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiography

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary echography
Study: NCT02697656

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help
Description: Self-help resources on obtaining employment and coping with chronic pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
Study: NCT00652600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: ER Capsules, 160 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderal-LA
Description: ER Capsules, 160 mg, single-dose